The incidence of squamous cell carcinoma of the oral tongue is rising in young non-smoking women: An international multi-institutional analysis.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 04 2020
revised: 14 06 2020
accepted: 22 06 2020
pubmed: 6 7 2020
medline: 24 6 2021
entrez: 5 7 2020
Statut: ppublish

Résumé

Increasing evidence is accumulating for an alarming rising incidence of oral tongue SCC in a younger cohort, particularly in developed countries. The aim of this study is to analyse the change in incidence of OSCC in patients under the age of 45 in developed nations in the Asia-Pacific region. Population data was extracted from the Australian Cancer Incidence and Mortality 2017 database and National Registry of Diseases Office, Singapore to allow calculation of the incidence in the Australian and Singaporean populations. This was compared to multi-institutional data from four tertiary Australian institutions. The inclusion criteria were as follows: a) diagnosis of primary SCC of the mobile tongue; b) treatment with curative intent; c) complete histopathologic data; d) complete adjuvant treatment data; e) follow up data. Analysis of ACIM data demonstrated that there was a significant increase in the incidence of tongue SCC in those under the age of 45 in the Australian and Singaporean populations (p < 0.001). When analysed for gender, the incidence of tongue SCC increased at a significantly higher rate in females than males (p < 0.001). Similarly, in the multi-institutional analysis including 1814 patients, the number of females under the age of 45 with tongue SCC significantly increased over time (p < 0.001), with the proportion of smokers in this cohort decreasing over time. The incidence of tongue SCC is rising in young females in developed nations in the Asia Pacific region, in keeping with observed epidemiological trends worldwide.

Identifiants

pubmed: 32622292
pii: S1368-8375(20)30311-0
doi: 10.1016/j.oraloncology.2020.104875
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104875

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Laveniya Satgunaseelan (L)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Johns Hopkins Drive via Missenden Road, Camperdown, NSW 2050, Australia; Central Clinical School, University of Sydney, Parramatta Road, Camperdown, NSW 2050, Australia. Electronic address: Laveniya.Satgunaseelan@health.nsw.gov.au.

Benjamin M Allanson (BM)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Johns Hopkins Drive via Missenden Road, Camperdown, NSW 2050, Australia. Electronic address: Benjamin.Allanson@health.nsw.gov.au.

Rebecca Asher (R)

NHMRC Clinical Trials Centre, University of Sydney Parramatta Road, Camperdown, NSW 2050, Australia. Electronic address: Rebecca.Asher@ctc.usyd.edu.au.

Rithvik Reddy (R)

John Hunter Hospital, Lookout Rd, New Lambton Heights, NSW 2305, Australia. Electronic address: Rithvik.Reddy@health.nsw.gov.au.

Hubert T H Low (HTH)

Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia.

Michael Veness (M)

Department of Radiation Oncology, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia; Westmead Clinical School, University of Sydney, Hawkesbury Road, Westmead, NSW 2145, Australia. Electronic address: Michael.Veness@health.nsw.gov.au.

N Gopal Iyer (N)

National Cancer Centre, Singapore, 11 Hospital Drive, Singapore 169610, Singapore.

Robert I Smee (RI)

Nelune Comprehensive Cancer Centre, 64-66 High St, Randwick, NSW 2031, Australia; Faculty of Medicine, University of New South Wales, 18 High Street, Kensington, NSW 2052, Australia. Electronic address: Robert.Smee1@health.nsw.gov.au.

Carsten E Palme (CE)

Central Clinical School, University of Sydney, Parramatta Road, Camperdown, NSW 2050, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address: Carsten.Palme@lh.org.au.

Ruta Gupta (R)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Johns Hopkins Drive via Missenden Road, Camperdown, NSW 2050, Australia; Central Clinical School, University of Sydney, Parramatta Road, Camperdown, NSW 2050, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address: Ruta.Gupta@health.nsw.gov.au.

Jonathan R Clark (JR)

Central Clinical School, University of Sydney, Parramatta Road, Camperdown, NSW 2050, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address: Jonathan.Clark@lh.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH